

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

BD CellQuest Pro

RRID:SCR_014489

Type: Tool

Proper Citation

BD CellQuest Pro (RRID:SCR_014489)

Resource Information

URL: https://www.bdbiosciences.com/documents/15_cellquest_prosoft_analysis.pdf

Proper Citation: BD CellQuest Pro (RRID:SCR_014489)

Description: A software for acquiring and analyzing flow cytometry data. The user can create plots with elements like regions, gates, statistics, markers, and annotated text. The software can also be used for batch analysis or quality control of analysis. Results can be exported and saved., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Resource Type: data acquisition software, data processing software, software application, software resource

Keywords: data analysis, flow cytometry data acquisition and analysis

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: BD CellQuest Pro

Resource ID: SCR_014489

Record Creation Time: 20220129T080320+0000

Record Last Update: 20260821T194022+0000

Ratings and Alerts

No rating or validation information has been found for BD CellQuest Pro.

No alerts have been found for BD CellQuest Pro.

Data and Source Information

Usage and Citation Metrics

We found 3939 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cheema PS, et al. (2026) Identification and validation of novel small molecule inhibitors targeting FoxM1-DNA binding domain with anti-cancer potential. *Biochimica et biophysica acta. Molecular cell research*, 1873(7), 120193.

Greenman M, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. *Cancer research communications*, 5(5), 774.

Santin NG, et al. (2025) Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. *Cancer research communications*, 5(9), 1611.

Mehdipour M, et al. (2025) Mitochondrial specific antioxidant MitoPBN mitigates oxidative stress and improves mitochondrial function in cryopreserved ram sperm. *Scientific reports*, 15(1), 10526.

Xing C, et al. (2025) Hspa13 Deficiency Impaired Marginal Zone B Cells Regulatory Function and Contributed to Lupus Pathogenesis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(8), e2413144.

Break MKB, et al. (2025) Synthesis, in vitro and in silico studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity via G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II. *Journal of enzyme inhibition and medicinal chemistry*, 40(1), 2501377.

Krapež G, et al. (2025) In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting. *Antibodies (Basel, Switzerland)*, 14(1).

Mangione RM, et al. (2025) DNA lesions can frequently precede DNA:RNA hybrid accumulation. *Nature communications*, 16(1), 2401.

Du J, et al. (2025) NGR-Modified CAF-Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(12), e2410918.

Guo R, et al. (2025) Aberrant lipid profiles and lymphocyte counts in systemic sclerosis population, reassessing predictive value for concurrent cardiovascular diseases. *Frontiers in immunology*, 16, 1530909.

Romão CM, et al. (2025) Expression of ABCB1, ABCC1, and LRP in Mesenchymal Stem Cells from Human Amniotic Fluid and Bone Marrow in Culture-Effects of In Vitro Osteogenic and Adipogenic Differentiation. *International journal of molecular sciences*, 26(2).

Yamashita AS, et al. (2025) Repurposing the anthelmintic drug mebendazole in combination with radiation therapy in an isocitrate dehydrogenase mutant glioma model. *Neuro-oncology advances*, 7(1), vdaf066.

Ding B, et al. (2025) Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling. *Frontiers in immunology*, 16, 1515605.

Tajadura-Ortega V, et al. (2025) Identification and characterisation of vaginal bacteria-glycan interactions implicated in reproductive tract health and pregnancy outcomes. *Nature communications*, 16(1), 5207.

Yang J, et al. (2025) KLC3 activates PI3K/AKT signaling and promotes ovarian cancer cell proliferation and migration through COL3A1. *Oncology reports*, 53(6).

Elchaninov A, et al. (2025) Cellular effects of splenectomy on liver regeneration after 70% resection. *Frontiers in cell and developmental biology*, 13, 1561815.

Cheng M, et al. (2025) Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling. *Cell death discovery*, 11(1), 169.

Bolovan LM, et al. (2025) Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study. *Biomedicines*, 13(6).

Liu L, et al. (2025) Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer. *iScience*, 28(1), 111612.

Matur E, et al. (2025) Impact of Lithium on the Immune System: An Investigation of T-Cell Subpopulations and Cytokine Responses in Rats. *Biological trace element research*, 203(2), 944.